A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(11 sites)

United States

Local Institution - 0011, Detroit, Michigan

Local Institution - 0026, Buffalo, New York

Local Institution - 0005, Durham, North Carolina

University Hospitals Cleveland Medical Center, Cleveland, Ohio

SCRI Oncology Partners, Nashville, Tennessee

Italy

Local Institution - 0001, Rozzano, Milano

Japan

Local Institution - 0020, Hirakata, Osaka

Local Institution - 0018, Chuo-ku, Tokyo

Romania

Local Institution - 0023, Timișoara, Timiș County

Local Institution - 0003, Craiova

Spain

Local Institution - 0009, Madrid